Pacira BioSciences, Inc. PCRX EXPAREL — Total net product sales

Other product segments

Similar metrics at other companies

ESPRProduct sales, net — Total Revenues

$43.4M+24.3%

ARDXProduct sales, net — Total revenues

$93.37M+37.7%

TVTXTotal net product sales — Total Revenue

$124.49M+64.1%

MIRMProduct sales, net — Product sales, net

$159.88M+43.3%

XER

XERSProduct revenue, net — Product revenue, net

$82.45M+42.6%

TARSProduct sales, net — Total revenues

$145.39M+85.6%

Questions, answered.

What is Pacira BioSciences, Inc.'s EXPAREL — total net product sales?

Pacira BioSciences, Inc. (PCRX) reported EXPAREL — total net product sales of $143.27M in Q1 2026.

How has Pacira BioSciences, Inc.'s EXPAREL — total net product sales changed year-over-year?

Pacira BioSciences, Inc.'s EXPAREL — total net product sales increased by 4.9% year-over-year, from $136.53M to $143.27M.

What is the long-term trend for Pacira BioSciences, Inc.'s EXPAREL — total net product sales?

Over 4 years (2021 to 2025), Pacira BioSciences, Inc.'s EXPAREL — total net product sales has grown at a 3.2% compound annual growth rate (CAGR), from $506.52M to $575.13M.

What does EXPAREL — total net product sales mean?

This metric represents the total revenue generated from the sale of a specific pharmaceutical product after accounting for returns, rebates, and discounts. It serves as a primary indicator of market adoption, product demand, and the commercial success of the company's core therapeutic offering. Tracking this figure allows investors to assess the growth trajectory and revenue contribution of the product within the broader portfolio.